The effort to end the global HIV epidemic may soon have a powerful new tool in its arsenal. Imagine replacing a daily pill with a single, once-a-month dose to prevent HIV. This isn’t a distant dream; it’s a reality moving into the final stages of clinical trials. An investigational drug, MK-8527, has shown significant promise as a once-monthly oral option for HIV pre-exposure prophylaxis (PrEP). Following a mid-stage study results presented at the 13th International AIDS Society Conference (IAS 2025), this potential game-changer is advancing to large-scale phase III trials, offering a new ray of hope for more convenient and accessible HIV prevention.
Why a Monthly PrEP Pill Matters More Than You Think
While existing PrEP options are highly effective, they come with challenges. The current standard, a daily oral pill, requires strict adherence that can be difficult for some to maintain. More recent innovations, like the twice-yearly lenacapavir injection, have been celebrated but aren’t suitable for everyone. Some individuals have a fear of needles, while others find the requirement of visiting a clinic for administration a significant barrier.
A once-monthly oral pill combines the simplicity of taking a pill with the convenience of a long-acting formula. In fact, a recent survey published in the Journal of Acquired Immune Deficiency Syndromes revealed that a monthly oral PrEP option was the most preferred modality for men who have sex with men compared to what is currently available. As Dr Rebeca Plank of MSD Research Laboratories noted, this oral alternative could represent a “paradigm shift” making it easier for people to start and continue with PrEP and expanding delivery beyond traditional clinics to settings that offer more flexibility and privacy.
How Does MK-8527 Work?
MK-8527 is a novel nucleoside reverse transcriptase translocation inhibitor (NRTTI). In simple terms, it attacks the HIV virus in two distinct ways. It stops a key enzyme, reverse transcriptase, from moving along the viral RNA. It acts as a defective building block that terminates the process HIV uses to copy its genetic material into DNA.
This drug is a successor to a similar compound, islatravir, whose development for PrEP was halted after studies showed it could cause a decline in immune cells (lymphocytes) at high doses. Encouragingly, MK-8527 does not appear to carry the same safety concerns. Early studies demonstrated that it had promising antiviral activity and reached protective levels in HIV-negative volunteers without any notable safety issues.
What Did the Phase II Trial Reveal?
The phase II study (NCT06045507) provided the robust data needed to move forward. The trial enrolled 350 adults with a low likelihood of HIV exposure across the United States, Israel, and South Africa. Participants were randomly assigned to receive one of three doses of MK-8527 or a placebo every four weeks for up to six months.
The results were overwhelmingly positive. Professor Kenneth Mayer of Fenway Health and Harvard Medical School reported that MK-8527 was well-tolerated, with a safety profile remarkably similar to the placebo. The most common side effects were mild to moderate headache, nausea, and fatigue, occurring at similar rates across all groups. Crucially, there were no clinically significant changes in laboratory tests, and no participants acquired HIV during the study.
Fast-Acting and Forgiving
One of the most exciting findings from the trial was the drug’s pharmacokinetics – how it’s absorbed and processed by the body. Protective concentrations of MK-8527 were achieved within 24 hours of the first dose, and possibly even sooner.
For those in the higher dose groups, these protective levels were sustained for slightly longer than the 28-day dosing interval. This creates what researchers called a “cushion of forgiveness of about a week if people take a pill late”. This built-in flexibility is a major advantage for real-world use, offering peace of mind and more consistent protection even if a dose is delayed.
What to Expect from Phase III Trials
With these strong results, Merck, in partnership with the Gates Foundation, is launching two large-scale phase III trials to confirm the drug’s efficacy and safety in diverse, real-world populations.
EXPRESSIVE-10: This study will enrol nearly 4,600 sexually active young women and adolescent girls in Kenya, South Africa, and Uganda.
EXPRESSIVE-11 (NCT07044297): Set to start in August 2025, this trial will enrol about 4,400 sexually active people across 16 countries, including gay men, transgender women and men, and nonbinary individuals.
In both trials, the monthly MK-8527 pill will be compared against the current standard of care, daily oral Truvada or its generic equivalents. If these trials are successful, advocates suggest that the drug could potentially become available by 2028, marking a significant milestone in HIV prevention.
The Future of Long-Acting HIV Medication
The development of MK-8527 is part of a broader, exciting trend in HIV medicine towards less frequent dosing for both prevention and treatment. Researchers are making significant strides in developing long-acting formulas to ease the burden of daily medication. For instance, combination pills for HIV treatment, such as islatravir plus lenacapavir, are being evaluated as a potential once-weekly oral option. This shift towards more convenient, long-acting antiretrovirals signals a future where managing HIV is simpler and more integrated into people’s lives.
Your Proactive Health Journey Starts Today
The prospect of a once-monthly PrEP pill is incredibly exciting, but the fight against HIV requires action today. While we anticipate these future innovations, highly effective prevention tools are already at your disposal. Taking control of your sexual health is paramount and you don’t have to wait.
At Shim Clinic, we provide comprehensive guidance on the best HIV prevention strategies for your lifestyle. Whether you’re considering HIV PrEP to protect yourself proactively or need urgent access to HIV PEP after a potential exposure, our experienced medical team is here to help. Regular screening is the cornerstone of sexual wellness, which is why our STD clinic offers confidential and reliable HIV testing and screening for other infections. We can help you understand your risk, interpret your HIV symptoms, and create a personalised health plan. Take a decisive step towards protecting yourself and your partners by exploring your options with us.